Altimmune, Inc. (ALT)
3.155
-0.04
(-1.41%)
USD |
NASDAQ |
Aug 26, 16:00
3.16
0.00 (0.00%)
After-Hours: 20:00
Altimmune Total Liabilities (Quarterly) : 53.00M for June 30, 2026
Total Liabilities (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 53.00M |
| March 31, 2026 | 51.64M |
| December 31, 2025 | 55.04M |
| September 30, 2025 | 32.85M |
| June 30, 2025 | 28.98M |
| March 31, 2025 | 15.10M |
| December 31, 2024 | 15.80M |
| September 30, 2024 | 14.49M |
| June 30, 2024 | 20.82M |
| March 31, 2024 | 15.42M |
| December 31, 2023 | 16.54M |
| September 30, 2023 | 16.18M |
| June 30, 2023 | 15.60M |
| March 31, 2023 | 19.35M |
| December 31, 2022 | 21.64M |
| September 30, 2022 | 20.25M |
| June 30, 2022 | 15.37M |
| March 31, 2022 | 20.79M |
| December 31, 2021 | 19.73M |
| September 30, 2021 | 27.64M |
| June 30, 2021 | 15.98M |
| March 31, 2021 | 17.81M |
| December 31, 2020 | 19.24M |
| September 30, 2020 | 33.29M |
| June 30, 2020 | 23.02M |
| Date | Value |
|---|---|
| March 31, 2020 | 12.34M |
| December 31, 2019 | 8.538M |
| September 30, 2019 | 7.004M |
| June 30, 2019 | 5.751M |
| March 31, 2019 | 6.052M |
| December 31, 2018 | 6.438M |
| September 30, 2018 | 13.18M |
| June 30, 2018 | 15.78M |
| March 31, 2018 | 14.37M |
| December 31, 2017 | 14.35M |
| September 30, 2017 | 17.28M |
| June 30, 2017 | 14.87M |
| March 31, 2017 | 2.677M |
| December 31, 2016 | 6.193M |
| September 30, 2016 | 4.156M |
| June 30, 2016 | 3.680M |
| March 31, 2016 | 3.108M |
| December 31, 2015 | 3.213M |
| September 30, 2015 | 3.224M |
| June 30, 2015 | 4.280M |
| March 31, 2015 | 5.442M |
| December 31, 2014 | 3.704M |
| September 30, 2014 | 5.244M |
| June 30, 2014 | 4.359M |
| March 31, 2014 | 6.049M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Liabilities (Quarterly) Benchmarks
| Amgen, Inc. | 83.95B |
| Protalix Biotherapeutics, Inc. | 38.93M |
| Taysha Gene Therapies, Inc. | 83.17M |
| Humacyte, Inc. | 106.83M |
| Liquidia Corp. | 326.80M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 527.21M |
| Shareholders Equity (Quarterly) | 474.21M |
| Debt to Equity Ratio | 0.076 |
| Current Ratio | 26.77 |
| Net Debt Paydown Yield | -1.16% |